Opportunities
Every ranked opportunity in the current evidence set, with the dimensions that could not be scored shown as unscored rather than as zero.
14 of 14
- 01sell84.2
Sitagliptin
timingdepthaccess- Strongest catalyst
- 14 SEPT 2026 7-Nitroso-3-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo-[4,3-a]pyrazine (NTTP)
- SimSon coverage
- 159 observed products
- Buyer candidates
- 6
Medium confidenceMedium because competitor scarcity could not be scored from public evidence. - 02sell67.3
Bedaquiline
timingdepthadjacency- Strongest catalyst
- 13 SEPT 2026 N-nitroso-desmethyl-bedaquiline
- SimSon coverage
- 43 observed products
- Buyer candidates
- None in evidence
Medium confidenceMedium because competitor scarcity could not be scored from public evidence. - 03sell60.3
Dapagliflozin
depthadjacencyaccess- Strongest catalyst
- 30 SEPT 2041 Orange Book patent 12409186*PED expiry
- SimSon coverage
- 177 observed products
- Buyer candidates
- 21
Medium confidenceMedium because competitor scarcity could not be scored from public evidence. - 04sell58.7
Isavuconazonium
timing- Strongest catalyst
- 13 SEPT 2026 N-nitroso-isavuconazonium
- SimSon coverage
- 18 observed products
- Buyer candidates
- None in evidence
Medium confidenceMedium because competitor scarcity could not be scored from public evidence. - 0557.0
Baxdrostat
timingadjacency- Strongest catalyst
- 15 MAY 2026 baxdrostat
- SimSon coverage
- 10 observed products
- Buyer candidates
- None in evidence
Medium confidenceMedium because competitor scarcity could not be scored from public evidence. - 06sell56.6
Orforglipron
timingdepthadjacency- Strongest catalyst
- 01 APR 2026 orforglipron
- SimSon coverage
- 36 observed products
- Buyer candidates
- None in evidence
Medium confidenceMedium because competitor scarcity could not be scored from public evidence. - 07sell53.9
Avatrombopag
timingdepth- Strongest catalyst
- 27 JUL 2027 Orange Book patent 7638536 expiry
- SimSon coverage
- 58 observed products
- Buyer candidates
- None in evidence
Medium confidenceMedium because competitor scarcity could not be scored from public evidence. - 08build53.7
Rusfertide
gaptiming- Strongest catalyst
- 28 AUG 2026 rusfertide
- SimSon coverage
- No listing observed
- Buyer candidates
- None in evidence
Medium confidenceMedium because market activity and competitor scarcity could not be scored from public evidence. - 09watch42.9
Tirzepatide
depth- Strongest catalyst
- 29 DEC 2041 Orange Book patent 12295987 expiry
- SimSon coverage
- 110 observed products
- Buyer candidates
- None in evidence
Medium confidenceMedium because competitor scarcity could not be scored from public evidence. - 10build39.6
Sonrotoclax
gaptiming- Strongest catalyst
- 13 MAY 2026 sonrotoclax
- SimSon coverage
- No listing observed
- Buyer candidates
- None in evidence
Medium confidenceMedium because competitor scarcity could not be scored from public evidence. - 11build38.9
Iberdomide
gaptiming- Strongest catalyst
- 13 AUG 2026 iberdomide
- SimSon coverage
- No listing observed
- Buyer candidates
- None in evidence
Medium confidenceMedium because competitor scarcity could not be scored from public evidence. - 12watch38.8
Semaglutide
depthadjacency- Strongest catalyst
- 16 FEB 2041 Orange Book patent 11318191 expiry
- SimSon coverage
- 180 observed products
- Buyer candidates
- None in evidence
Medium confidenceMedium because competitor scarcity could not be scored from public evidence. - 13build37.6
Vepdegestrant
gaptiming- Strongest catalyst
- 01 MAY 2026 vepdegestrant
- SimSon coverage
- No listing observed
- Buyer candidates
- None in evidence
Medium confidenceMedium because competitor scarcity could not be scored from public evidence. - 14build36.4
Islatravir
gaptimingadjacency- Strongest catalyst
- 20 APR 2026 doravirine and islatravir
- SimSon coverage
- No listing observed
- Buyer candidates
- None in evidence
Medium confidenceMedium because competitor scarcity could not be scored from public evidence.
Scroll sideways for the full table
| Rank | Opportunity | Action | Shapes | Score | Confidence | Strongest catalyst | Coverage | Buyers | Not scored |
|---|---|---|---|---|---|---|---|---|---|
| 01 | Sitagliptin | sell | timingdepthaccess | 84.2 | Medium confidence | 14 SEPT 20267-Nitroso-3-(trifluoromethyl)-5,6,7,8-tetrahydro[1,2,4]triazolo-[4,3-a]pyrazine (NTTP) | 159 | 6 | competitor scarcity |
| 02 | Bedaquiline | sell | timingdepthadjacency | 67.3 | Medium confidence | 13 SEPT 2026N-nitroso-desmethyl-bedaquiline | 43 | — | competitor scarcity |
| 03 | Dapagliflozin | sell | depthadjacencyaccess | 60.3 | Medium confidence | 30 SEPT 2041Orange Book patent 12409186*PED expiry | 177 | 21 | competitor scarcity |
| 04 | Isavuconazonium | sell | timing | 58.7 | Medium confidence | 13 SEPT 2026N-nitroso-isavuconazonium | 18 | — | competitor scarcity |
| 05 | Baxdrostat | timingadjacency | 57.0 | Medium confidence | 15 MAY 2026baxdrostat | 10 | — | competitor scarcity | |
| 06 | Orforglipron | sell | timingdepthadjacency | 56.6 | Medium confidence | 01 APR 2026orforglipron | 36 | — | competitor scarcity |
| 07 | Avatrombopag | sell | timingdepth | 53.9 | Medium confidence | 27 JUL 2027Orange Book patent 7638536 expiry | 58 | — | competitor scarcity |
| 08 | Rusfertide | build | gaptiming | 53.7 | Medium confidence | 28 AUG 2026rusfertide | No listing observed | — | market activitycompetitor scarcity |
| 09 | Tirzepatide | watch | depth | 42.9 | Medium confidence | 29 DEC 2041Orange Book patent 12295987 expiry | 110 | — | competitor scarcity |
| 10 | Sonrotoclax | build | gaptiming | 39.6 | Medium confidence | 13 MAY 2026sonrotoclax | No listing observed | — | competitor scarcity |
| 11 | Iberdomide | build | gaptiming | 38.9 | Medium confidence | 13 AUG 2026iberdomide | No listing observed | — | competitor scarcity |
| 12 | Semaglutide | watch | depthadjacency | 38.8 | Medium confidence | 16 FEB 2041Orange Book patent 11318191 expiry | 180 | — | competitor scarcity |
| 13 | Vepdegestrant | build | gaptiming | 37.6 | Medium confidence | 01 MAY 2026vepdegestrant | No listing observed | — | competitor scarcity |
| 14 | Islatravir | build | gaptimingadjacency | 36.4 | Medium confidence | 20 APR 2026doravirine and islatravir | No listing observed | — | competitor scarcity |
Observations
Scored records that carry no actionable shape. The evidence is real and the score was computed the same way, but nothing in it points at a commercial move — so they are held here rather than ranked alongside opportunities.
- watchedoxaban39.1
Orange Book patent 9149532 expiry
- watchdoravirine35.5
Orange Book patent 10842751 expiry
Scroll sideways for the full table
| Molecule | Action | Score | Strongest catalyst | Coverage |
|---|---|---|---|---|
| Edoxaban | watch | 39.1 | 27 MAR 2028 Orange Book patent 9149532 expiry | 11 |
| Doravirine | watch | 35.5 | 28 NOV 2036 Orange Book patent 10842751 expiry | 3 |